Difference between revisions of "Pazopanib (Votrient)"
m |
|||
Line 18: | Line 18: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
+ | |||
+ | [[Category:Kinase inhibitors]] | ||
+ | [[Category:KIT inhibitors]] | ||
+ | [[Category:PDGFR inhibitors]] | ||
+ | [[Category:VEGF inhibitors]] |
Revision as of 03:14, 10 January 2014
General information
Class/mechanism: Tyrosine kinase inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors FGFR-1 and FGFR-3, cytokine receptor (Kit), interleukin-2 receptor inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). Interferes tumor angiogenesis, growth, and cancer progression.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Pazopanib (Votrient) package insert PDF pages 27-32[1]
- Pazopanib (Votrient) patient drug information (Chemocare)[3]
- Pazopanib (Votrient) patient drug information (UpToDate)[4]